JP2019517511A - 腫瘍を処置する方法において使用するための抗ｐｄ−１抗体 - Google Patents

腫瘍を処置する方法において使用するための抗ｐｄ−１抗体 Download PDF

Info

Publication number
JP2019517511A
JP2019517511A JP2018563090A JP2018563090A JP2019517511A JP 2019517511 A JP2019517511 A JP 2019517511A JP 2018563090 A JP2018563090 A JP 2018563090A JP 2018563090 A JP2018563090 A JP 2018563090A JP 2019517511 A JP2019517511 A JP 2019517511A
Authority
JP
Japan
Prior art keywords
antibody
tumor
stk11
months
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517511A5 (cg-RX-API-DMAC7.html
Inventor
ロビン・エドワーズ
ハン・チャン
ミシェル・クリアリー
ピーター・エム・シャボ
ジョセフ・ディ・シュスタコウスキー
パトリック・ビタツカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019517511A publication Critical patent/JP2019517511A/ja
Publication of JP2019517511A5 publication Critical patent/JP2019517511A5/ja
Priority to JP2022146466A priority Critical patent/JP2022188071A/ja
Priority to JP2025022545A priority patent/JP2025081454A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018563090A 2016-06-03 2017-06-02 腫瘍を処置する方法において使用するための抗ｐｄ−１抗体 Pending JP2019517511A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022146466A JP2022188071A (ja) 2016-06-03 2022-09-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
JP2025022545A JP2025081454A (ja) 2016-06-03 2025-02-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345658P 2016-06-03 2016-06-03
US62/345,658 2016-06-03
PCT/US2017/035798 WO2017210624A1 (en) 2016-06-03 2017-06-02 Anti-pd-1 antibody for use in a method of treating a tumor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022146466A Division JP2022188071A (ja) 2016-06-03 2022-09-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体

Publications (2)

Publication Number Publication Date
JP2019517511A true JP2019517511A (ja) 2019-06-24
JP2019517511A5 JP2019517511A5 (cg-RX-API-DMAC7.html) 2020-07-09

Family

ID=59067919

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018563090A Pending JP2019517511A (ja) 2016-06-03 2017-06-02 腫瘍を処置する方法において使用するための抗ｐｄ−１抗体
JP2022146466A Pending JP2022188071A (ja) 2016-06-03 2022-09-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
JP2025022545A Pending JP2025081454A (ja) 2016-06-03 2025-02-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022146466A Pending JP2022188071A (ja) 2016-06-03 2022-09-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
JP2025022545A Pending JP2025081454A (ja) 2016-06-03 2025-02-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体

Country Status (6)

Country Link
US (3) US20200325226A1 (cg-RX-API-DMAC7.html)
EP (1) EP3464369A1 (cg-RX-API-DMAC7.html)
JP (3) JP2019517511A (cg-RX-API-DMAC7.html)
KR (3) KR20250107295A (cg-RX-API-DMAC7.html)
CN (1) CN109476753A (cg-RX-API-DMAC7.html)
WO (1) WO2017210624A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
UA124379C2 (uk) 2015-08-11 2021-09-08 Усі Байолоджікс Айрленд Лімітед Нові антитіла проти білка pd-1
LT3377534T (lt) 2015-11-18 2025-08-11 Bristol-Myers Squibb Company Plaučių vėžio gydymas, panaudojant anti-pd-1 antikūno ir anti ctla-4 antikūno derinį
CN110678483B (zh) 2017-06-01 2023-09-22 百时美施贵宝公司 用抗pd-1抗体治疗肿瘤的方法
WO2019157124A1 (en) * 2018-02-08 2019-08-15 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
CA3090995A1 (en) * 2018-02-13 2019-08-22 Merck Sharp & Dohme Corp. Methods for treating cancer with anti-pd-1 antibodies
MA51844A (fr) * 2018-02-13 2021-05-19 Merck Sharp & Dohme Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
WO2019207030A1 (en) * 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
WO2020139941A1 (en) * 2018-12-27 2020-07-02 H. Lee Moffitt Cancer Center And Research Institute Inc. Treatment of stk11-loss cancers
EP3946625A1 (en) * 2019-03-28 2022-02-09 Bristol-Myers Squibb Company Methods of treating tumor
WO2021034890A1 (en) * 2019-08-19 2021-02-25 Pandion Therapeutics, Inc. Targeted immunotolerance with a pd-1 agonist
EP4387104A1 (en) 2022-12-13 2024-06-19 LX Semicon Co., Ltd. Analog-to-digital converter and semiconductor device having the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165422A1 (en) * 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2016081384A1 (en) * 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
TWI605828B (zh) 2008-12-09 2017-11-21 建南德克公司 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途
WO2011066389A1 (en) 2009-11-24 2011-06-03 Medimmmune, Limited Targeted binding agents against b7-h1
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
EP3403672A1 (en) 2011-04-20 2018-11-21 Medlmmune, LLC Antibodies and other molecules that bind b7-h1 and pd-1
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
KR102243062B1 (ko) * 2013-05-02 2021-04-21 아납티스바이오, 아이엔씨. 예정된 사멸-1에 대한 항체
WO2014194302A2 (en) 2013-05-31 2014-12-04 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-1
HUE060420T2 (hu) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
ES2753360T3 (es) * 2014-05-29 2020-04-08 Spring Bioscience Corp Anticuerpos contra PD-L1 y usos de los mismos
CN114702586A (zh) 2015-03-13 2022-07-05 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165422A1 (en) * 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2016081384A1 (en) * 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. 74(19_Supplement), JPN6022041354, 2014, pages 105, ISSN: 0005011384 *
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY (2016 APR.), 100, P.88-98, JPN6021023373, ISSN: 0004886986 *
JULIE BRAHMER: "NIVOLUMAB VERSUS DOCETAXEL IN ADVANCED SQUAMOUS-CELL NON-SMALL-CELL LUNG CANCER", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. VOL:373, NR:2, JPN5019005117, 9 July 2015 (2015-07-09), pages 123 - 135, ISSN: 0004886984 *
MODERN PATHOLOGY (2016), 29, P.753-763, PUBLISHED: 08 APRIL 2016, JPN6021023374, ISSN: 0004886985 *
ONCOIMMUNOLOGY, vol. VOL. 5, NO. 5,, JPN6022041353, March 2016 (2016-03-01), pages 1131379, ISSN: 0005011383 *

Also Published As

Publication number Publication date
US20250382368A1 (en) 2025-12-18
CN109476753A (zh) 2019-03-15
JP2022188071A (ja) 2022-12-20
EP3464369A1 (en) 2019-04-10
KR20250107295A (ko) 2025-07-11
US20220315657A1 (en) 2022-10-06
JP2025081454A (ja) 2025-05-27
WO2017210624A1 (en) 2017-12-07
KR20190015408A (ko) 2019-02-13
KR20230118713A (ko) 2023-08-11
US20200325226A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
US20220315657A1 (en) Anti-pd-1 antibody for use in a method of treating a tumor
US20250154257A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
JP2024063028A (ja) 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置
JP2024063023A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置
US20180155429A1 (en) Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
JP2019517498A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体
US20240124589A1 (en) Methods of treating urothelial carcinoma using an anti-pd-1 antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230314